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ABSTRACT 
In 1990-1991, in a national surveillance study, and in 1991-1992, in a follow-
up study, both by Thornsberry et al. (1993), ciprofloxacin data from various 
geographical and demographical institutions were collected. Several species of 
bacteria have shown resistance to ciprofloxacin and norfloxacin, but the degree of 
resistance to these drugs has not been reported for the Stockton area. To determine 
the extent of this resistance, Dameron Hospital antibiograms generated from 1990 to 
1994 were reviewed and compared. Results of the comparison show that 
susceptibility among the Gram-negative isolates, with the exception of Providencia 
stuartii, Acinetobacter lwoffi, and to a lesser extent Aeromonas hydrophila, has 
changed very little. Consistent with the national surveys, resistance of Pseudomonas 
aemginosa has not changed appreciably during the five-year period. 
Among the Gram-positive isolates that were tested against both ciprofloxacin 
for a five-year period (1990-1994) and norfloxacin for a three-year period (1992"' 
1994), increased resistance was seen among strains of Staphylococcus aureus, S. 
epidermidis, S. haemolyticus, and Enterococcus jaecalis, but not among strains of 
Staphylococcus saprophyticus, Streptococcus pyogenes, and S. agalactiae. To 
determine whether resistance to one fluoroquinolone occurs also to other 
fluoroquinolones, several isolates of Gram-positive cocci and P. aeruginosa from the 
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Gram-negative bacilli that showed resistance to either ciprofloxacin, norfloxacin, or 
both were selected from Dameron Hospital isolates and tested by the disk diffusion 
technique against ciprofloxacin, norfloxacin, ofloxacin, and lomefloxacin. The results 
indicate that differences do exist among these selected strains. Comparison of the in-
vitro effectiveness of the various quinolones confirms that methicillin-resistant 
staphylococci (S. aureus, S. epidermidis, and S. haemolyticus) exhibit a higher degree 
of resistance to the four fluoroquinolones compared with the methicillin-susceptible 
strains of the same species. Resistance of the enterococci (Enterococcus jaecalis and 
E. jaecium) is also high. Generally, when the four fluoroquinolones were compared 
with each other, ofloxacin seemed to have better in vitro activity. 
Resistance to the quinolones consists of two proposed mechanisms: ( 1) 
mutation of one or both of the structural genes of the A and B subunits of DNA gyrase 
and (2) decreased drug accumulation due either to lower uptake by the cell or 
enhanced effiux out of the cell. These mechanisms of resistance are reviewed. 
v 
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INTRODUCTION 
"Fluoroquinolones such as ciprofloxacin, which may be administered 
orally or intravenously, exhibit a wide spectrum of antibacterial activity. 
This broad spectrum of activity, combined with ease of administration, 
excellent absorption, high tissue permeability, and favorable safety profile 
have made these agents highly desirable in the treatment of a wide variety 
of infections. 
Although the fluoroquinolones have proven to be highly effective 
antimicrobial agents, some concern has arisen that resistance may develop 
rapidly among previously susceptible organisms. This concern was 
supported by a series of published reports demonstrating the development 
of resistance in P. aen~ginosa, S. aureus (predominantly methicillin-
resistant) and other organisms" (Thornsberry et al., 1993: 4). 
Based on two studies, 1990-91 and 1991-92, Thornsberry et al. (1993) 
reported the results of a national surveillance of bacterial resistance based on data from 
162 institutions in 3 8 states. The susceptibility data for the two years involved over 
921,000 isolates representing 56 genera and 176 species or groups of Gram-positive 
and Gram-negative bacteria. Ciprofloxacin was the only fluoroquinolone reported and 
its susceptibility data was based on 441,218 isolates. 
Using lVITC (minimum inhibitory concentration) data and interpretations based 
on National Committee for Clinical Laboratory Standards (NCCLS) publication M7-
A2, Thornsberry et al. (1993) found 86% of the 1991-92 isolates susceptible (S) to 
ciprofloxacin, 3.1% intermediate (1), and 10.9% resistant (R) compared with 88.2%, 
4.6%, and 7.2% respectively for 1990-91. 
This led to the conclusion that the occurrence of limited ciprofloxacin 
resistance in clinically important bacterial species is well established, especially in 
methicillin-resistant staphylococci and that various mechanisms of resistance have been 
determined, but the extent of this resistance is less well known. Since the degree and 
extent of this resistance to ciprofloxacin and other quinolones for the Stockton area is 
unknown, it was proposed that I conduct a retrospective study beginning with 1990, 
the year that ciprofloxacin came to be used at Dameron hospital, and extending 
through 1994. This retrospective study, to determine degree and extent of resistance 
to ciprofloxacin and other quinolones among bacterial isolates from Dameron Hospital 
in Stockton, California, became my primary objective. 
Thornsberry's data does not include susceptibility results to norfloxacin or 
other quinolones. Dameron Hospitall\tficrobiology Laboratory has been testing 
norfloxacin since 1990, and during January and February of 1994, tested ofloxacin and 
lomefloxacin. During these five years, a number of articles appeared comparing the in 
vitro activity of fluoroquinlones with one another; among the recent ones are 
Wadworth and Goa (1991), Walker and Wright (1991), Bongaerts and Hoogkamp-
Korstanje (1993), Canton et al. (1993), Marshall et al, (1993), Tanaka et al. (1993), 
Chang et al. (1994), and Jones et al. (1994). Since mechanisms of action ofthe 
quinolones are likely to be the same and that factors responsible for ciprofloxacin 
resistance are also assumed to be involved in cross-resistance to the other quinolones 
(Cambau and Gutmann, 1993), I decided to test this assumption by comparing in vitro 
activities of the four fluoroquinolones on various bacterial species including both 
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methicillin-resistant and methicillin-susceptible strains. I would like to emphasize at 
this point that these data and results are based on in vitro studies and the discussion 
will be limited to in vitro results. Neither pharmacokinetics of the different quinolones 






The quinolones are a group of synthetic antimicrobial drugs that are highly 
active against bacteria but show low toxicity to eukaryotic cells. Selectivity to 
bacterial cells is due to the unique features of their DNA gyrase, or topoisomerase II, 
an intracellular enzyme which was originally identified by Gellert et al. (1976) and 
upon which quinolones are believed to act. Prokaryotic topoisomerase II is required 
in DNA synthesis, specifically to insert negative supercoils into the covalently closed 
circular bacterial chromosome, an essential step for the cell to accommodate the very 
long chromosome (Smith, 1986). In addition to inserting negative supercoils, 
topoisomerase II provides the infonnation required for such functions as transcription, 
DNA repair, recombination, and transposition (Wolfson and Hooper, 1985; von 
Rosentiel and Adam, 1994). In mammalian cells, this function is perfonned by 
topoisomerase I (Crumplin, 1986). 
This class of chemotherapeutic agents can be defined, according to Wentland 
( 1990), as !-substituted 1 ,4-dihydro-4-oxo-3-pyridinecarboxylic acids with an 
additional ring fused to positions 5 and 6 (Fig. 1 ). The antimicrobial characteristics of 
these compounds were discovered in the late 1950s (Wentland, 1990) when 
researchers at the Sterling Winthrop Research Institute isolated several byproducts of 
the antimalarial agent chloroquine. One such byproduct, 7 -chloro-1-ethyl-1, 4-
4 
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dihydro-4-oxo-3-quinolinecarboxylic acid (Fig. 2), was found to have sufficient in 
vitro antibacterial qualities to render it wonhy of :further study. This compound 
provided the basis for further analog design and synthesis leading to the introduction 
of nalidixic acid, 1-ethyl-7 -methyl-1 ,8-napthyridine-4-one-3-carboxylic acid (Fig. 3 ), 
the first clinically useful quinolone (Lesher et al., 1962). 
Shortly after the introduction of nalidixic acid, it became evident that this drug 
was oflimited therapeutic value because of its weak potency against Gram-positive 
bacteria, rapid development of resistance to it in vitro and in vivo, irrespective of 
dosage (Ronald et al., 1966), and its lack of activity against Pseudomonas (Neu, 
1989). Although its low serum level due to rapid renal clearance limits its use for 
treatment of systemic bacteremias, it renders it ideal for the treatment of urinary tract 
infections caused by Gram-negative bacteria. 
Subsequent work on these compounds during the 1970s produced oxolinic 
acid (Fig. 4) and cinoxacin (Fig. 5), two 4-quinolones with a common skeleton, 4-oxo-
1,4-dihydroquinolone (Fig. 6). These, however, had only marginal improvements over 
nalidixic acid (Norris and Mandell, 1988). Other 4-quinolones produced shortly after 
were acrosoxacin, pipedemic acid, and piromidic acid. Definite progress was made 
when it was discovered that the addition of a fluorine atom to 4-oxo-1 '4-
dihydroquinolone extends its in vitro activity to the Gram-positive bacteria. The 
substitution of fluorine at position 6 appears also to improve the compound's binding 
to DNA gyrase and penetration across the bacterial cell wall (Neu, 1989). This 4-
quinolone with 6-fluorine became the basic quinolone from which other 
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fluoroquinolones were derived. Norfloxacin (Fig. 7) was the first to be synthesized 
through the addition of an ethyl group at position 1, a carboxyl group at position 3, 
and a piperazinyl group at position 7. As the first fluorquinolone, norfloxacin 
demonstrated improved Gram-positive and Gram-negative antibacterial activity 
including that against staphylococci and pseudomonads, respectively. With the 
development ofnorfloxacin, the fluoroquinolone era had begun (Wentland, 1990). 
Since the synthesis of norfloxacin, many other fluoroquinolones have been 
synthesized including amifloxacin, difloxacin, flumequine, levot1oxacin, spartloxacin, 
tosufloxacin, ciprofloxacin, enoxacin, ofloxacin, pefloxacin, temafloxacin (withdrawn 
from worldwide markets in 1992), fleroxacin, and lomefloxacin (von Rosenstiel and 
Adam, 1994), all containing a similar skeleton. The quinolones most commonly used in 
Stockton hospitals at the start of this study were nalidixic acid, cinoxacin, norfloxacin, 
ciprofloxacin, ofloxacin, and lomefloxacin. The various chemical groups that are 
added to manufacture ciprotloxacin, ofloxacin and lometloxacin are shown in figures 
8, 9, and 10, respectively. 
Fluorine at position 6, as stated earlier, appears to be the most active 
substituent leading to improved penetration across the bacterial cell wall and > 1 0-fold 
increase in gyrase inhibition. According to Neu (1989) and Domagala (1994), the 
carboxyl group and keto group at positions 3 and 4, respectively, mediate the binding 
of these compounds to DNA gyrase. The proximity of these two groups probably 
contributes to passage across the bacterial cell wall due to a chelating effect that 
allows increased entry of the compound. Microbiological and pharmacokinetic 
6 
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properties are greatly influenced by the substituents at the N-1 or C-7 positions. The 
cyclopropyl group at the N-1 position, as in ciprofloxacin, appears to be the most 
potent substitution (Domagala, 1994) against Enterobacteriaceae and Pseudomonas 
aeruginosa compared to the addition of an ethyl group as in norfloxacin and 
lomefloxacin (Neu, 1989). The greatest modification of all positions has been at C-7; 
excellent in vitro activity is seen with a piperazinyl group, as in norfloxacin and 
ciprofloxacin, or with a methylpiperazinyl group as in ofloxacin. Both of these groups 
increase the potency of these compounds towards both Gram-positive and Gram-
negative bacteria (Neu, 1989) and greater in vivo efficacy (Domagala, 1994). Alkyl 
substitutions of the piperazinyl ring at position 7, such as in lomefloxacin, further 
increase serum half-life and activity against Gram-positive bacteria (Domagala, 1994). 
Position 8 controls efficiency in vivo with an optimal addition of a fluorine as in 
lomefloxacin. A ring formed between C-8 and N-1, as in ofloxacin, provides improved 
Gram-positive and anti-anaerobic activity (Neu, 1989; Domagala, 1994). The 
substituent at position 5 controls in vitro potency with optimal groups being Nfu, OH, 
and CHJ, and greatest improvements being in Gram-positive organisms (Domagala, 
1994) evident in fluoroquinolones not included in this study. Comprehensive reviews 
of structure-activity relationships of the fluoroquinolones have been published (Chu 




MATERIALS AND 1\ffiTHODS 
This study is based, in part, on data accumulated between 1990 and 1994 at 
Dameron Hospital and partly on selected species of bacteria tested by me (in-house 
testing) during 1993. 
Dameron Hospital Antibiogram 1990-1994 The number of isolates 
encountered in the retrospective study consisted of 10,764 strains belonging to 20 
species of Gram-negative bacilli (Table 1) and 6445 belonging to 7 species of Gram-
positive cocci (Table 2). 
In-House testing The data of 1990-1992 suggested that most resistance to 
the fluoroquinolones was among the Gram-positive cocci and in Pseudomonas 
aeruginosa among·the Gram-negative bacilli. The sample selected, in most cases, 
consisted of strains that showed resistance to either ciprofloxacin, norfloxacin, or both. 
These included 208 isolates of Gram-positive cocci: 8 methicillin-susceptible 
Staphylococcus aureus (MSSA), 26 methicillin-resistantS. aureus (l\1RSA), 7 
methicillin-susceptible Staphylococcus epidermidis (MSSE), 64 methicillin-resistantS. 
epidermidis (MRSE), 27 Staphylococcus haemolyticus, 44 Enterococcusfaecalis, 19 
E. faecium, 6 Streptococc..'ltS agalactiae, 7 S. bovis; and 21 isolates of Pseudomonas 
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aeruginosa. These specimens, collected during 1993, were tested against 4 
fluoroquinolones: ciprofloxacin, norfloxacin, ofloxacin, and lomefloxacin. 
Antimicrobial drugs The quinolones were obtained from various sources: 
ciprofloxacin disks (5 ug) were donated by Miles Pharmaceutical Division (West 
Haven, Conneticut) through the courtesy of their local representative; norfloxacin (10 
ug), ofloxacin (5 ug), and lomefloxacin (10 ug) were purchased from Becton 
Dickenson Microbiology Systems (Cockeysville, Maryland). 
Media Media used included Mueller-Hinton antimicrobial susceptibility 
plates for staphylococci and P. aeruginosa; mannitol salt agar (MSA) plates, eosin 
methylene blue (EMB) plates, tryptic soy agar (TSA) slants, and saline solution were 
prepared according to the manufacturer's instructions or standard procedures and 
autoclaved at 250 F, 15 lbs pressure for 20 minutes. For streptococci and enterococci, 
Mueller-Hinton blood agar plates (BAP) were purchased from PML Microbiologicals 
(Prepared Media Laboratory, Tualatin, OR). 
Stock cultures Isolates were brought from Dameron Hospital on TSA, 
blood agar, or chocolate agar slants. The slants were subcultured on the following 
media to ascertain purity: MSA for staphylococci, BAP for streptococci and 
enterococci, and EMB for P. aeruginosa. Following 24-hour incubation, two to three 
colonies from each plate were selected, transferred to appropriate slants, and 
9 
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incubated overnight and used as stock culture. Stock cultures were kept in the 
refrigerator at 2-8 C. 
Antimicrobial susceptibility testing Disk diffusion susceptibility testing was 
performed using the proper Mueller-Hinton plates: clear Mueller-Hinton for 
staphylococci and P. aen1ginosa and BAP tbr streptococci and enterococci. The 
stock culture of each isolate was removed from the refrigerator and reincubated for 2-
4 hours at 35 C. While in their logarithmic growth phase, an inoculum was taken from 
each slant and introduced into 5.0 mi saline to obtain a turbidity equivalent to 0.5 
McFarland Standard (0.05 mi barium chloride in 9.95 mi 1% sulfuric acid) and a cell 
density of approximately Idl/ml. The turbidity was estimated visually against the 
Standard tube and adjusted, if necessary, by either adding inoculum or sterile saline. A 
sterile swab (Hardwood Products Company) was then dipped into the saline 
suspension, drained by pressing against the inside of the saline tube above the level of 
the fluid, and a single streak was made in the center of the appropriate Mueller-Hinton 
susceptibility plate. The same swab was then used to spread the organisms on the 
streak line in three dimensions, horizontal, vertical, and diagonal, to ensure uniform 
inoculation of the entire surface of the plate. Antimicrobial disks of ciprofloxacin, 
norfloxacin, ofloxacin, and lomefloxacin were applied by gently pressing the disks with 
sterile forceps to ensure adherence to the plates. Plates were incubated at 35 C for 18 
to 24 hours. The diameter of the zone of inhibition for each disk was measured using 
a millimeter ruler and transmitted light. When excessive confluent growth or 
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contamination was observed, the entire test for that organism was repeated. The 
observed zones of inhibition were interpreted according to NCCLS document M2-A4 
(Appendix) and recorded. 
Quality control testing Quality control strains, purchased from American 
Type Culture Collection, of Escherichia coli (ATCC 25922), Pseudomonas 
aemginosa (ATCC 27853), Staphylococcus cmreus (ATCC 29213), Enterococcus 
faecalis (ATCC 29212), and Streptococcus bovis (ATCC 49147) were tested weekly 





These results are based on information accumulated between 1990 and 1994 
from Dameron Hospital and on data obtained from in-house testing. It should also be 
noted that the data from Dameron Hospital is based on MIC results whereas in-house 
testing utilizes disk diffusion methods. Between 1990 and 1994, 10 different types of 
MIC panels for Gram-negative bacilli and three different types ofMIC panels for 
Gram-positive cocci have been manufactured by Microscan (Microscan; Sacramento, 
California) and used at Dameron Hospital. Three Gram-negative MIC panels were 
used for isolates from the urinary tract and seven for isolates from other body sites. 
Certain panels contained all four quinolone types while others contained only 
ciprofloxacin and norfloxacin. The results of the retrospective study are summarized in 
tables 1 and 2 and those of in-house testing in tables 3-12. 
Retrospective study 
Table 1 shows results of the activities of the 4 fluoroquinolones on 20 species 
of Gram-negative bacteria, 16 Enterobacteriaceae and 4 non-Enterobacteriaceae. A 
total of 10,764 isolates were tested for susceptibility to ciprofloxacin, 5246 isolates to 
norfloxacin, 328 to ofloxacin, and 204 to lomefloxacin (only 1994 data available for 
ofloxacin and lomefloxacin). 
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Ciprofloxacin susceptibility Among the 20 Gram-negative species, 9 
Enterobacteriaceae (Escherichia coli, Shigella sonnei, Klebsiella pneumoniae, 
Citrobacter diversus, C. amalonaticus, Proteus mirabilis, P. vulgaris, Morganel/a 
morganii, and Salmonella spp.) showed 100% susceptibility to ciprofloxacin; for 6 
species, susceptibilities varied from 99.7% to 95.4% (Klebsiella oxytoca, 99.7%; 
Enterobacter cloacae, 99.6%; E. aerogenes, 99.4%; Citrobacter freundi, 99.3%; 
Providencia rettgeri, 96.2%; Serratia marcescens, 95.4%); and Providencia stuartii, 
85.4%. Among the 4 non-Enterobacteriaceae, Aeromonas hydrophilia and 
Pseudomonas aemginosa showed susceptibilities of95.9%, Acinetobacter lwoffi 
92.9%, andXanthamonas maltophilia 75.6% for this quinolone. Among the 
Enterobacteriaceae, only P. stuartii showed susceptibility of less than 90% (85.4%) to 
ciprofloxacin, and X maltophilia was least susceptible among the non-
Enterobacteriaceae. A consistent downward trend was evident among A. hydrophila 
strains. 
Norfloxacin susceptibility Among the 16 species of Enterobacteriaceae, 8 
(S. sonnei, K. oxytoca, E. cloacae, C. diversus, C. amalonaticus, P. vulgaris, 
!vi. morganii, and Salmonella spp.) displayed 100% susceptibility to norfloxacin; 8 
·showed·susceptibilities between 99.6% and 60% (E. coli, 99.6%; K. pneumoniae, 
99.1 %; P. mirabilis, 99.1%; E. aerogenes, 98.3%; C. freundii, 94.3%; P. rettgeri, 
84.6%; S. marcescens, 78.4%; and P. stuartii, 60%). Among the non-
13 
Enterobacteriaceae, the 4 species showed the following susceptibilities to norfloxacin: 
A. hydrophilia, 1 00%; P. aernginosa, 90%; A. lwoffi, 88.2%; and X maltophilia, 0%. 
Again the least susceptible among the Enterobacteriaceae was P. stuartii ( 60% ); 
among the non-Enterobacteriaceae, all four strains of X maltophilia showed no 
susceptibility. 
Ofloxacin susceptibility Among the 15 species of Gram-negative 
Enterobacteriaceae, 12 showed 1 00% susceptibility during the one year tested 
(S. sonnei, K pneumonia, K oxytoca, E. cloacae, E. aerogenes, · S. marcescens, 
C. diversus, C. amalonaticus, P. mirabilis, P. vulgaris, M morganii, and Salmonella 
spp.). Escherichia coli isolates showed 99% susceptibility, C.jreundii 94%, and 
P. stuartii 50%. Only two species of non-Enterobacteriaceae were tested: A. lwoffi 
displayed 90% susceptibility and P. aen1ginosa 81%. Among the Enterobacteriaceae, 
P. stuartii again showed least susceptibility (50%). 
Lomefloxacin susceptibility Among the 12 species of Enterobacteriaceae, 8 
showed 1 00% susceptibility during the one year tested (K pneumoniae, K oxytoca, 
E. cloacae, E. aerogenes, C. diversz1s, P. mirabilis, P. vulgaris, and M morganii); the 
remaining 4 displayed the following susceptibilities: E. coli, 98%; C. jreundii, 83%; 
and S. marcescens and P. stuartii, 0%. Among the non-Enterobacteriaceae, 
P. aeruginosa showed susceptibility of76% while A. lwoffi displayed 67%. P. stuartii 
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was also the least susceptible among the Enterobacteriaceae; however, it should be 
emphasized that only one strain was tested. 
Among the Gram-negative bacilli, 13 of20 species (65%) show greater than 
99% susceptibility to ciprofloxacin, 12 of20 (60%) to norfloxacin, 13 of 17 (76.5%) 
to ofloxacin, and 8 of 14 (57. 1%) to lomefloxacin. The Enterobacteriaceae showed a 
high level of susceptibility to all quinolones, while the non-Enterobacteriaceae showed 
relatively lower susceptibility levels. For the Gram-negative bacteria tested, P. stuartii 
and X maltophilia displayed non-susceptibility rates to ciprofloxacin, nortloxacin, 
ofloxacin, and lomefloxacin that exceeded 1 0%; P. aeroginosa displayed both 
ofloxacin and lomefloxacin non-susceptibility rates of 19% and 24% respectively, and 
P. rettgeri and S. marcescens showed norfloxacin non-susceptibility rates of 15.4% 
and 21.6% repectively. 
When the 4 quinolones are compared to one another, certain trends are 
evident. Ciprofloxacin and norfloxacin seemed to be equally effective on most species 
with the exception of S. marscens, P. rettgeri, and P. shtartii; 95.4% of S. marscens, 
96.2% of P. rettgeri, and 85.4% of P. stuartii were susceptible to ciprotloxacin 
compared with 78.4%, 84.6%, and 60%, respectively, to norfloxacin. These 
observations suggest that ciprofloxacin is more effective in vitro than norl1oxacin 
against certain species of Gram-negative bacilli. The number of isolates of these 3 
species tested against ofloxacin and lomefloxacin was too small (P. rettgeri was not 
tested) to allow for comparison. When the activities of the 4 quinolones were 
compared with species having 10 or more isolates, table 1 shows that ciprofloxacin, 
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norfloxacin, otloxacin, and lometloxacin are equally eftective against E. coli, K 
pneumoniae, K. oxytoca, E. cloacae, C. freundii, and P. mirabilis. Comparing the in 
vitro efficacy of the quinolones against P. aeruginosa, the data suggest that 
ciprotloxacin is the most effective (95.9%) compared with norfloxacin (90%), 
otloxacin (81%), and lometloxacin (76%). 
Table 2 shows the activities of two quinolones, ciprotloxacin over a five year 
period and norfloxacin over a three year period and their effect, on 7 species of Gram-
positive cocci. A total of 6445 organisms were tested against ciprotloxacin and 1525 
against norfloxacin. 
Ciprofloxacin susceptibility Among the staphylococci tested, 
S. saprophyticus isolates were 100% susceptible. S. aureus showed 85.6% 
susceptibility compared to 70.8% and 56 .I% for S. epidermidis and S. haemolyticus, 
respectively. Among the streptococci, S. pyogenes showed 99.3% susceptibility and 
S. agalactiae 98.9%. E. faecalis showed 89.3% susceptibility. A susceptibility trend 
is evident for S. epidermidis decreasing every year from 1990 to 1994 with an average 
of70.8% susceptibility; S. haemolyticus showed a similar trend from 1990 to 1994 
and an average of 56.1% susceptibility. S. haemolyticus was the least susceptible 
overall. 
Norfloxacin susceptibility Among the staphylococci tested, S. saprophyticus 
was 100% susceptible, S. aureus 77.1 %, S. epidermidis 61.3%, and S. haemolyticus 




S. agalactiae 83.9%. Efaecalis displayed 77.9% susceptibility. Again, S. 
haemolyticus showed the least susceptibility. 
Methicillin-resistant staphylococci are known to exhibit resistance to many 
antibiotics (hence also the designation multiply-resistant staphylococci), including the 
fluoroquinolones, compared with methicillin-susceptible ones. The data in table 2 
does not, however, distinguish between the two groups. 
Ofloxacin and lomefloxacin were not tested. Overall, 83.9% of the Gram-
positive isolates were susceptible to ciprofloxacin and 75.6% to norfloxacin. 
In-house testing 
The second component of this study was to compare the results of the 4 
quinolones with one another. In-house testing was conducted in 1993 using the disk 
diffusion method on a group of Gram-positive cocci belonging to 7 species in 9 
groups: [(methicillin-susceptible S. aureus (MSSA), methicillin-resistantS. aureus 
(MRSA), methicillin-susceptible S. epidermidis (MSSE), methicillin-resistant S. 
epidermidis (MRSE), S. haemolyticus, E. faecalis, E faecium, S. agalactiae, and S. 
bovis)] and P. aeruginosa. These species were selected because the 1992 antibiogram 
had shown that resistance to ciprofloxacin and norfloxacin was common among these 
Gram-positive cocci; P. aeruginosa was also selected to compare with Thornsberry et 
al. (1993) who had concluded that resistance by this organism to ciprofloxacin is on 
the increase. 
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There were 208 Gram-positive and 21 P. aeruginosa isolates tested against 
each of the 4 quinolones (ciprofloxacin, norfloxacin, ofloxacin, and lomefloxacin). 
Tables 3 through 13 summarize these results. 
Methicillin-Susceptible Staphvlococcus aureus (MSSA) Table 3 shows the 
results of the 4 quinolones tested on 8 isolates; one isolate (12.5%) was completely 
resistant to all quinolones (pattern 1); another (12.5%) was susceptible to all4 
quinolones (pattern 2). Patterns 3 through 7 show a mixture of reactions of S, I, and 
R. Highest susceptibility was seen to ofloxacin with 7 strains (87.5%) susceptible 
followed by ciprofloxacin (62.5%), norfloxacin (25%) and lomefloxacin (25%). 
Methicillin-Resistant Staphylococcus aureus (MRSA) Table 4 shows only 2 
patterns for the 26 isolates, and 25 isolates (96%) exhibited complete resistance to all 
4 quinolones (pattern 1), with only 1 strain (4%) showing suceptibility to all 
quinolones (pattern 2). 
Methicillin-susceptible Staphylococcus epidermidis (MSSE) Table 5 shows 
a predominance of complete resistance to a114 quinolones (pattern 1) in 5 of the 7 
isolates (71.4%). Ofthe other 2 strains, one (14.3%) showed complete susceptibility 
(pattern 2), and one (14.3%) intermediate susceptibility to 3 quinolones and resistance 
to lomefloxacin. Thus, 71.4% of the isolates showed susceptibility to ciprofloxacin, 
norfloxacin, and ofloxacin; 85. 70/o of the isolates were resistant to lomefloxacin. 
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Methicillin-Resistant Staphvlococcus epidermidis (MRSE) Table 6 displays 
the results oftesting of64 strains and shows 7 different patterns of activity. A 
predominance of resistance to all four quinolones was exhibited in 49 strains (76.6%) 
compared with 2 (3.1%) that were completely susceptible (pattern 2). Patterns 3 
through 7 showed a mixture of reaction ofS, I, and R to the fluoroquinolones. 
Overall, 96.9% of the isolates were resistant to lomefloxacin, 92.2% to norfloxacin, 
79.7% to ofloxacin, and 78.1% to ciprofloxacin. 
Staphylococcus haemolyticus Table 7 shows the results of 27 isolates tested; 
all 27 isolates displayed complete resistance to all four quinolones. 
Enterococcus (aecalis Table 8 shows the results of testing of 44 strains. 
Twenty-seven isolates ( 61.4%) exhibited resistance to all 4 quinolones (pattern 1) and 
2 (4.5%) show complete susceptibility (pattern 2). For 7 strains, pattern 3 showed 
intermediate susceptibility to 3 quinolones but resistance to lomefloxacin. Overall, 42 
isolates (95.5%) were resistant to lomefloxacin, 70.5% to norfloxacin, 68.2% to 
ciprofloxacin, and 63.6% to ofloxacin. 
Enterococcus faecium Table 9 shows results of the 19 strains tested. 
Thirteen isolates (68.4%) were resistant to all4 quinolones (pattern 1), 5 strains 
(26.3%) showed resistance to ciprofloxacin and lomefloxacin and intermediate 
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susceptibility to norfloxacin and ofloxacin (pattern 2), and one strain (5.3%) had 
intermediate susceptibility to ciprofloxacin, norfloxacin, and ofloxacin but was 
resistant to lomefloxacin. No isolates exhibited susceptibility to any of the 4 
quinolones, and all I9 (I 00%) were resistant to lomefloxacin. 
Streptococcus agalactiae Table I 0 shows the results of testing of 6 isolates. 
Five different patterns of S, I, and R were evident with no strong trends for any strain 
except that there was I 00% resistance to lomefloxacin; 66.7% of the isolates showed 
susceptibility to ofloxacin. 
Streptococcus bovis Table II shows results of testing on 7 strains and 5 
different patterns. No strong trends were apparent; one isolate (I4.3%) was resistant 
to all4 quinolones (pattern 1). Of the 7 isolates, 85.7% showed resistance to 
lomefloxacin and highest susceptibility was to ofloxacin (42.9%). 
Pseudomonas aeruginosa Table I2 shows the results oftesting of2I 
isolates; resistance to all 4 quinolones (pattern I) was exhibited by II isolates 
(52.4%), and one (4.8%) showed susceptibility to all4 quinolones. The rest of the 
isolates (38.1 %) displayed a mixture of patterns (patterns 3-8). Overall, 95.2% were 
resistant to lomefloxacin, followed by 90.5% to ofloxacin, 61.9% to norfloxacin, and 
57 .I% to ciprofloxacin. 
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Ciprofloxacin susceptibility Table 13 shows that 62.5% ofMSSA isolates 
were susceptible compared with 3.8% ofMRSA. MSSE showed a susceptibility of 
14.3% compared with 3.1% for MRSE. The other isolates showed susceptibilities 
between 0% andJO%: S. haemolyticus, 0%; E.faecalis, 4.5%; E.faecium, 0%; S. 
agalactiae, 16.7%; S. bovis, 28.6%; and P. aentginosa, 14.3%. 
Norfloxacin susceptibility Table 13 shows that 25% of MSSA isolates were 
susceptible compared with 3.8% for MRSA. MSSE showed 14.3% susceptible 
compared to 3 .1% for MRSE. The other isolates showed susceptibilities between 0% 
and 20%: S. haemolyticus, 0%; E. faeca/is, 4.5%; E. faecium, 0%; S. agalactiae, 0%; 
S. bovis, 14.3%; and P. aemginosa, 19%. 
Ofloxacin susceptibility Table 13 shows that 87.5% ofMSSA isolates were 
susceptible compared with 3.8% for MRSA; S. epidermidis isolates were 14.3% 
susceptible compared with 6.3% for MRSE. The other species showed susceptibilities 
between 0% and 66.7%: S. haemolyticus, 0%; E. faecal is, 11.4%; E. faecium, 0%; S. 
aga/actiae, 66. 7%; S. bovis, 57.1 %; and P. aemginosa, 4.8%. 
Lomefloxacin susceptibility Table 13 shows that 25% ofMSSA isolates 
were susceptible compared with 3.8% for MRSA. MSSE showed 14.3% 
susceptibility compared to 3 .1% for MRSE. The remaining species showed 
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susceptibilities between 0% and 4.8%: S. haemolyticus, 0%; E. faecalis, 4.5%; E. 
faecium, 0%; S. agalactiae, 0%; S. bovis, 0%; and P. aeruginosa, 4.8%. 
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DISCUSSION 
The results ofthis study are compared with those ofThornsberry et al. (1993) 
(national survey) tbr the same species (Tables 14 and 15). Overall, 99.7% of the 
Enterobacteriaceae showed susceptibility to ciprofloxacin compared with 97.4% in the 
national survey. The non-Enterobacteriaceae represent a heterogeneous group: 
Pseudomonas aentginosa and Xanthomonas maltophilia are. members of the order 
Pseudomonadales; Acinetobacter lwoffi and Aeromonas hydrophila are neither related 
to each other nor to the Pseudomonadales. The data in Table 14 show that there are 
some differences between the Dameron data and the national data with respect to A. 
lwoffi (92.9% compared with 86.4%), P. aentginosa (95.9% compared with 86.4%), 
and X maltophi/ia (75.6% compared with 33.6%). Table 14 also indicates similar 
patterns and trends of susceptibility among Dameron isolates and those of the national 
data. 
The results of susceptibility testing of the Enterobacteriaceae to ciprofloxacin 
indicate that 15 of 16 species (93.8%) showed susceptibility greater than 90% (95.4%-
100%), Providencia stuartii exhibiting susceptibility of85.4%. When the Dameron 
Hospital data are compared with the national data for the same species, the national 
data show 13 of 16 (81.3%) with a susceptibility over 90% (93.1%-99.6%). 
Differences are seen in Serratia marcescens 95.4% compared with 88.2% and 
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P. rettgeri 96.2% compared with 88.8%. Both data indicate that P. stuartii is less 
susceptible to ciprofloxacin than other Enterobacteriaceae, Dameron Hospital 
reporting susceptibility of85.4% compared to national survey of69.7%. In every 
instance, the susceptibility rates were higher for each of the species for Dameron 
isolates compared with the national survey. 
Dameron Hospital data show the other three quinolones, norfloxacin, 
ofloxacin, and lomefloxacin, to be equally effective in vitro for most 
Enterobacteriaceae; exceptions to this are seen in S. marcescens and P. stuartii which 
show reduced susceptibility to nortloxacin and lomefloxacin, and P. stuartii exhibiting 
reduced susceptibility to otloxacin. 
Overall, with a few exceptions, the Enterobacteriaceae remain highly 
susceptible to ciprotloxacin in vitro. This conclusion is supported by Walker and 
Wright (1991) and Jones et al. (1994). King and Phillips (1986) showed that the N-1 
cyclopropyl group gives ciprotloxacin its most potent in vitro activity against 
Enterobacteriaceae. The same conclusion was reached by Chu and Fernandes (1989) 
with respect to activity against P. aeruginosa. Thornsberry et al. (1993), as in this 
study, found a large decrease in susceptibility for P. stuartii, but indicated that the 
majority or resistant strains came from five of 162 institutions, of which Dameron 
Hospital could have been one; they also suggested that quinolone resistance tends to 
be localized within endemic areas rather than being spread out geographically. 
Table 14 also compares the percent susceptibility of the four non-
Enterobacteriaceae species from Dameron Hospital with the national survey. Again 
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the percent susceptibility reported for the Dameron isolates is higher than that reported 
in the national survey. Thornsberry et al. ( 1993) suggested that increased resistance to 
ciprotloxacin has appeared among a few strains of P. aemginosa but that, in general, 
most strains are still susceptible. The data from Dameron Hospital for the five years 
(Table 1) support this trend with similar results for nortloxacin. Factors that may 
explain differences between the two data (95.9% for Dameron compared to 86.4%) 
include greater consistency in reading of susceptibilities at a single hospital (Dameron 
Hospital) compared with the national results derived from 162 hospitals, and also 
extent of the usage of ciprotloxacin in various regions of the country. Overall, the 
Dameron data show that lomefloxacin and ofloxacin are not as effective as norfloxacin 
and ciprot1oxacin against P. aemginosa. 
The in-house testing, based, as indicated earlier, on a biased sample in which 
20 of the 21 strains were specifically selected because of their resistance to one or 
more quinolones, suggests that lomefloxacin shows least in vitro efficacy against 
P. aemginosa. This conclusion is supported by Wadworth and Goa (1991). Other 
reports indicate that ciprofloxacin is the most potent of the quinolones, as shown by 
King and Phillips (1986), Walker and Wright (1991), Wadworth and Goa (1991), von 
Rosenstiel and Adam (1994). Thornsberry et al. (1993) conclude that ciprofloxacin-
resistant strains exist, yet most are still susceptible without a marked change in 
susceptibility; Dameron Hospital results support this conclusion. 
Among the non-Enterobacteriaceae, Dameron Hospital results show that 
norfloxacin is relatively less effective than the other quinolones against X ma/tophilia, 
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and otloxacin is least effective against A. lwoffi. Thornsberry et al. (1993) found a 
1 0% decrease in susceptibility in A. lwoffi but also stated that the change could be due 
to a change in the taxonomic nomenclature for this genus. They also found a large 
majority of X maltophilia isolates to be resistant to ciprofloxacin in contrast with 
Dameron isolates that are susceptible. 
Comparing the results of the Dameron study with the national survey data for 
the Gram-positive isolates, Table 15 suggests that, with the exception of 
Staphylococcus saprophyticus, Streptococcus pyogenes, and S. agalactiae, generally 
the other Gram-positive cocci (Staphylococcus aureus, S. epidermidis, S. 
haemolyticus, and Enterococcusfaecalis) are less susceptible to ciprotloxacin 
compared with most of the Enterobacteriaceae. The susceptibilities of these four 
species of Gram-positive cocci range from 56.1% to 89.3% compared with 52.3% to 
79.1% from the national study. The differences are especially significant in the percent 
susceptibility of E. faecalis isolates from Dameron Hospital which show susceptibility 
of89.3% compared with 58.3% in the national study. This higher susceptibility of 
Dameron isolates is the result of improper reporting by the Microbiology Department 
(F. M. Nahhas, personal communication). In late 1994, the microbiologists at 
Dameron accidenta1ly discovered that 18-24 hour incubation of the Gram-positive 
panels is not long enough and, thus, does not give an accurate reading for 
ciprofloxacin and norfloxacin. When these panels were incubated for an additional 24 
hours, in about 30% of the cases, resistance was found at 48 hours which was not 
evident at 24 hours. The hospital has already corrected this problem by not reporting 
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the results of ciprofloxacin and norfloxacin at 24 hours. It is of interest to note that 
such a problem was not encountered with the Gram-negative panel. 
Among the staphylococci, Dameron data show that S. saprophyticus is 100% 
susceptible to ciprofloxacin and norfloxacin (not tested in-house). Compared with S. 
saprophyticus, other staphylococci showed relatively lower susceptibility rates than 
the other species tested, with S. aureus being highest and S. haemolyticus being the 
lowest. Both S. epidermidis and S. haemolyticus show trends of decreasing 
susceptibility to ciprofloxacin and norfloxacin over the five- and three-year period, 
respectively, with unexplainable results for S. aureus. In-house data show that all four 
quinolones were I 00% resistant to S. haemolyticus. Fuchs ( 1991) reported that the 
staphylococci that show resistance to ciprofloxacin are the methicillin-resistant S. 
haemolyticus; this study confirs that conclusion. In-house data also show that, among 
the IVISSE and NIRSE, the majority of strains were resistant to aU four quinolones. 
Also, in-house results show that ofloxacin was most effective against MSSA followed 
by ciprofloxacin; all four quinolones showed equally poor susceptibility results for 
1\tiR.SA. Thornsberry et al. ( 1993) report that lower susceptibility to ciprofloxacin is 
associated with methicillin-resistant strains of staphylococci, especially MRSA and 
MRSE. Furthermore, most methicillin-susceptible staphylococci remain susceptible to 
ciprofloxacin while most methicillin-resistant staphylococci are clearly resistant and, 
thus, follow a definite pattern. Interestingly enough, however, mechanisms of 
resistance for the two drugs are very different: methicillin-resistance is due to 
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production of penicillin-binding proteins whereas ciprofloxacin resistance is due to 
alterations in DNA gyrase. 
Among the enterococci, Dameron data show that E. jaecalis is relatively less 
susceptible to ciprofloxacin and norfloxacin than streptococci. Over the five- and 
three-year period, decreasing susceptibility trends can be observed for ciprofloxacin 
and norfloxacin. In-house data shows that there is relatively high resistance among 
enterococci to all four quinolones, E. faecium showing no susceptibility to any of the 
four quinolones. Both E. faecalis and E. faecium show highest resistance to 
lomefloxacin, and E. jaecalis shows highest susceptibility to ofloxacin. Thornsberry et 
al. (1993) found that isolates of enterococci were evenly distributed between 
ciprofloxacin-susceptible and ciprofloxacin-resistant strains; yet, Dameron data show 
higher overall susceptibility to ciprofloxacin due to reasons previously mentioned. In 
contrast, in-house data show very little susceptibility. Schaberg et al. ( 1992) report 
that resistance to ciprofloxacin appeared in enterococci over a five-year period (1985-
1990) in one hospital in spite of specific restricted access to quinolone use. Walker 
and Wright ( 1991) report that the genus Enterococcus is among those least susceptible 
to most quinolones; Piddock et al. ( 1994) report that E. faecium tends to be more 
resistant to antimicrobial agents than E. faecalis. 
Among the streptococci, Dameron data show ciprofloxacin and norfloxacin to 
be relatively highly effective against S. pyogenes and S. agalactiae. In-house data 
show that lomefloxacin was least effective and ofloxacin most effective on 
S. agalactiae and S. bovis. Piddock (1994) reported that the epidemiology of 
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quinolone resistance has not been documented and high resistance not reported for 
streptococci as they have been for (ciprofloxacin-resistant) staphylococci. 
The development of resistance to old and new antimicrobials is of great 
concern in clinical medicine today (Davies, 1994). When a new antibiotic is 
introduced, many species seem to adapt and develop various degrees of resistance to 
that drug; thus, the development of resistance to the quinolones is not surprising 
(Thornsberry et al., 1993). 
Quinolones bind and inhibit DNA gyrase inducing cleavage of the bacterial 
DNA backbone thus producing a bactericidal effect fVV alker and Wright, 1991 ); yet, 
even with the extensive research, the precise interaction between DNA gyrase and 
quinolones is incompletely understood (Maxwell, 1992). Prokaryotic DNA gyrase is 
composed of 4 subunits, 2 A monomers and 2 B monomers. Gellert et al. ( 1977) 
discovered that the A subunits fi.mction to insert nicks into each strand of DNA, while 
the B subunits contain sites involved in A TP hydrolysis providing energy for the 
supercoiling reaction of the nicked DNA. Following the supercoiling, the A subunits 
lock the supercoils into the chromosome. The specific action of nalidixic acid, the first 
quinolone studied, on chromosomal replication was found to cause an abnormal 
accumulation of DNA single-stranded precursors to form, each representing a domain 
of the chromosome (Crumplin & Smith, 1976). Gellert et al. (1977) proposed that the 
4-quinolones prevent the sealing of the staggered nicks in the DNA usually resealed by 
the A subunits of DNA gyrase. Smith (1986) submitted additional evidence that 
shows that mutations in the B subunits accord a change in bacterial sensitivity to the 4-
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quinolones; thus, both A and B subunits are affected when 4-quinolones attack the 
DNA gyrase. 
Two general mechanisms of resistance to the quinolones have been proposed: 
(I) the alteration ofDNA gyrase and (2) decreased dnrg accumulation due either to 
lower uptake or enhanced ~fflux. Mutation in the stnrctural genes of the A and B 
subunits, gyrA and gyrB, has been found to be the cause of alteration of DNA gyrase 
since Gellert et al. ( 1977) identified the first quinolone-resistance gene in E. coli, the 
product of nalA, a component of DNA gyrase. Biochemical analysis has shown that 
when purified A and B subunits from susceptible and resistant strains were compared 
for quinolone resistance, the A subunit from a quinolone-resistant strain combined 
with the B subunit of a susceptible strain forming a quinolone-resistant DNA gyrase 
(Gootz & Martin, 1991). Yoshida et al. (1988, 1990) and Wadworth and Goa (1991) 
found through genetic analysis that a single point mutation causing a single amino acid 
change in the gyrA gene in E. coli, the quinolone-resistance determining region, was 
found to be responsible for the modification of subunit A leading to decreased affinity 
of DNA gyrase to the quinolones. Twenty-one gyrA mutants of E. coli have been 
genetically studied and 11 different mutations described both in vivo and in vitro. 
Similar findings were reported for S. aureus; it is not yet" established if the same 
mutations have the same effect on other bacterial species (Cambau and Gutmann, 
1993). Complementation experiments with the gyrA gene· confirmed that quinolone-
resistant strains of different Gram-positive (Nakanishi, et al., 1991) and Gram-negative 
species (Power et al., 1992) exhibit mutations in the gyrA genes. 
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Mutation in the gyrB gene can also confer quinolone resistance evidenced by 
differences in lower resistance patterns from that of the gyrA gene (Cambau and 
Gutmann, 1993 ). Yoshida et al. ( 1991) tested quinolone resistant gyrB mutants of E. 
coli K116 and found two types of mutants. Type 1 mutants were resistant to all 
quinolones and type 2 resistant to acidic quinolones but hypersusceptible to the 
amphoteric quinolones (norfloxacin, ciprofloxacin, and ofloxacin). 
Decreased cell wall permeability and increased quinolone efflux have also been 
found to cause resistance (Cambau and Gutmann, 1993). Quinolone-resistant mutants 
often show decreased quinolone uptake. For E. coli, most mutations are associated 
with a decrease in the amount of the OmpF porin, an outer membrane protein that 
forms water-filled channels through which certain small hydrophilic antimicrobial 
agents penetrate the outer membrane. In the mutants studied (nfxB, cfx:B, norB, 
nfxC), a gene encodes for an antisense rnRi'J"A interfering with translation of OmpF 
mRNA, decreasing synthesis ofOmpF (Hooper et al., 1992), and thus decreasing cell 
wall permeability. In P. aentginosa, differences in outer membrane proteins OprF 
(Piddock et al., 1991) and other proteins have been associated with decreased 
quinolone accumulation within mutants of this species. 
· Quinolone efflux, another possible cause of quinolone resistance, is a process 
by which quinolones are exported into or out of the bacterial cell and is the result of an 
energy-dependent inner membrane process. Resistance conferred by increased efflux 
is lower than resistance caused by the gyrA mutation but is still present often enough 
for sufficient resistance to occur during therapy (Cambau and Gutmann, 1993 ). 
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Fluoroquinolones have become widely used in clinical practice, and the 
increase in resistance toward them among methicillin-resistant staphylococci calls for 
justified concern in their use for long-term efficacy according to Cruciani and Bassetti 
(1994). 
My study indicates that resistance among the Gram-positive cocci in the 
Stockton community is not restricted to lVIRSA but also involves other staphylococci 
(S. epidermidis and S. haemolyticus), streptococci (S. aga/actiae and S. bovis), and 
enterococci (E. faecalis and E. faecium). In contrast, resistance toP. aemginosa has 




The retrospective study of the Gram-negative isolates showed that 
susceptibility of Enterobacteriaceae to ciprofloxacin and norfloxacin had changed very 
little over the five-year period, except for Providencia stuartii which showed a 
decreased susceptibility trend. Susceptibility of non-Enterobacteriaceae to 
ciprofloxacin and norfloxacin varied for different species tested and was relatively less 
than that of Enterobacteriaceae. Acinetobacter lwoffi showed decreased susceptibility, 
specifically for 1994 data, but this could be due to rearrangement of species in the 
genus Acinetobacter. Aeromonas hydrophila showed a decreasing susceptibility trend 
during 1993 and 1994, Pseudomonas aemginosa remained relatively consistently 
susceptible, and }(amhomonas maltophilia consistently showed lowest susceptibility. 
The few isolates of Providencia stuartii showed low susceptibility to ofloxacin and 
lomefloxacin. 
The retrospective study of the Gram-positive isolates showed that 
Staphylococcus saprophyticus was 100% susceptible to both ciprofloxacin and 
norfloxacin, while Staphylococcus haemolyticus showed relatively poor susceptibility 
against both fluoroquinolones. Staphylococcus epidermidis and Enterococcus jaecalis 
showed decreasing susceptibility trends against ciprofloxacin and norfloxacin over the 
years tested. Streptococcus pyogenes and Streptococcus agalactiae remained 
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relatively consistently susceptible to ciprofloxacin and norfloxacin. Generally, 
ciprofloxacin was relatively more effective against Gram-positive isolates than 
norfloxacin. 
The in-house study (a biased sample of Gram-positive and P. aemginosa 
isolates) showed that methicillin-resistant staphylococci had lower susceptibility to all 
four fluoroquinolones tested than did methicillin-susceptible staphylococci. Also, 
these four fluoroquinolones were relatively poorly effective against S. haemolyticus 
and the enterococci. Ofloxacin was most effective and lomefloxacin least effective 
against Gram-positive cocci compared with ciprofloxacin and norfloxacin. 
Ciprofloxacin was most effective against P. aemginosa. 







Definition of a quinolone 
1-substituted-1, 4-dihydro-4-oxo-3-pyridinecarboxylic acid with 
additional ring fused to positions 5 and 6 representing the position 





Byproduct of chloroquine 
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The first fluoroquinolone: addition of fluorine extends activity to 
Gram-positive bacteria and addition of piperazinyl group appears to 




Addition of the cyclopropyl group appears to improve activity 
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Table 2 Gram-positive surveillance isolates from Dameron Hospital: 
Susceptibility to ciprofloxacin and norfloxacin 
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0 C'IS ·u 0 )( co: 0 C'IS co: 0 t )( Cl) .... 0 E a. 0 t;: 0 Pattern# 0 z 0 ..J Total 
1 R R R R 1 
2 s s s s 1 
3 s I s I 2 
4 I I s I 1 
5 I R s I 1 
6 s s s I 1 
7 s I s s 1 -
Table 3 Methicillin-Susceptible Staphylococcus aureus 
c c 
't:; c 't:; 
C'IS ·u c C'IS )( )( 
0 C'IS ·u 0 co: )( C'IS co: 0 0 t 
)( Cl) .... 0 E a. 
0 0 = 0 Total Pattern# z 0 ..J 
1 R R R R 25 
2 s s s s 1 
Table 4 Methicillin-Resistant Staphylococcus aureus 
I iill!iliiiiild~!hiiiiiiifiMI\l-ifiltlll\tf fiff, n f"l r\tT'ft ,t.il .. ---·-
~-OF I~-----
II 
-· .. , b ·m ''"=" ,J,QLIL,;,,j!lli!l..e:.''-r .._' 1 l ll L.:. 
.5 c 
u c: ·u cu ·u c C'll >< >< 
0 cu ·u 0 ;:: >< cu '; 0 0 t >< - 0 E Q. 0 ;:: 0 Pattern# 0 z 0 ..J Total 
1 R R R R 5 
2 s s s s 1 
3 I I I R 1 
--- ----·--------
Table 5 Methicillin-Susceptible Staphylococcus epidermidis 
+-
' c: c: c c: ·u c ·u 
C'll ·u c cu >< >< 
0 cu ·u 0 ;:: >< C'll ;:: 
0 0 >< cu - t 0 E Q. 0 = 0 Pattern# 0 z 0 ..J Total 
·u c ·u 
C'll ·u c C'll >< >< 
0 cu ·u 0 
lj: >< C'll ;:: 0 0 t >< 
cu ... 0 E Q. 0 ;:: 0 
Pattern# 0 z 0 ..J Total 
1 R R R R 49 1 R R R R 27 
2 s s s s 2 
3 I R I R 7 Table 7 Staphylococcus haemolyticus 
4 I R R R 2 
5 I I s R 2 
6 R R I R 1 
7 I I I R 1 
Table 6 Methicillin-Resistant Staphylococcus epidermidis 
i\ 
I ':. i MOOllllUIII~I\'\-IDIIII\Iillffi:, 11n 1 II IDI\:Hh\11: 11\H\,11 :IIIII ""I !1!11 " .. ~~--
.j;o. 
N 
ib(ffiiiiillli ,IIISIIIMIAIIIIIIII-LID ::: ----
c ·u c 
Cl:l ·u )( 
0 Cl:l 
li: )( 
E 0 ;: 
Q. 0 
Pattern# 0 2 
1 R R 
2 s s 
3 I I 
4 R R 
5 I I 
6 I R 
7 R I 
8 I R 
9 I I 
Table 8 Enterococcus faeca/is 
c ·u c 
I'CJ ·u >< 
0 Cl:l 
li: >< 
0 0 ._ re Q. 0 
Pattern# 0 2 
1 R R 
2 R I 
3 I I 
Table 9 Enterococcus faecium 
c ·u 




li: 0 I 
0 ..J Total 1 
R R 27 
s s 2 
I R 7 
I R 2 
s R 2 
s R 1 
I R 1 
I R 1 
R R 1 
c ·u 
c Cl:l >< ·u 0 
Cl:l li: 
>< cu 
0 E ' 
li: 0 I 
0 ..J Total 
R R 13 
I R 5 
I R 1 
----- ---- ---~--~ 
+-vJ 
aii.iiiiiiiiiii.JIIAIHZINhiiilii-&L& ::: -----
c ·u c 
cu 'u c )( 
0 cu ·u 
10: 
)( cu 0 0 t 
)( ... 0 Q. 0 10: 
Pattern# 0 2 0 
1 R R I 
2 s I s 
3 I I s 
4 I R I 
L. . s ... __ l_ ____ 13.- --~ -
Table 10 Streptococcus aga/actiae 
c ·u c 
cu ·u c )( 
0 cu ·u 
10: 
)( cu e 0 )( t 0 Q. 0 10: 
Pattern# 0 2 0 
1 R R R 
2 s s s 
3 R R I 
4 I R s 
5 s I s 
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Rl ·c:; c >< 
0 Rl ·u 
li: >< Rl 0 0 'E >< ... 0 Q. 0 li: 
Pattern# 0 z 0 
1 R R R 
2 s s s 
3 I I R 
4 I R R 
5 R I R 
6 s s I 
7 I s R 
8 s s R 
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~ ~ ! a g (J (J 
i 8 
(J 
~ 0 ~ e 
l .e ~ .n Ill 
0 4.5 0 16.7 
27 44 19 6 
Table 13 Quinolone susceptibility for in-house isolates 
1 ·~ 1 Mmmtummtllmll,l••n•m'm'rm~,,.~~r., 1 ~~~~~ ,(,11,1([,11151"' ·'·" , , .. __ 
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~ .!2 5 t ~ ~ l a :a 1: 't: ~ ~ ~ ~ ~ Cll ~ u ! ~ -~ ~ ~ ~ Cll ~ l :a ~ a. ~ ! .... i ~ ~ ~ e Ill u J!! -!! ~ -!! Ill ,!! ,!! u u ~ ~ ~ e ~ ~ u ,!! j .a ... I ~ 1 ·i ,!! i l ~ u ~ I r:: Qj .a ! .a ~ .a t ~ ~ ~ 8 § 'S .§ tj ~ ~ .n £ £ l "1 :& 
100 100 100 99.7 99.6 99.4 95.4 99.3 100 100 100 100 100 96.2 85.4 100 ·---- -··---- ·-- -- ----- ----· -- -- --
4489 119 1179 290 571 166 241 409 87 68 795 44 251 26 41 108 
<-----------------------------------------------------------------99. 7 -----------------------------------------------------> 
_ 99~:!- ~~=~- ___!!~~?- ~!=~ --~L -~5.~ 88.~ .~1::~ ~3~! ~9.5 97 :!_ ~!!~~ 97.7 ~s.a 69.7199.6_ 
99040 520 27850 5314 13336 7262 6503 5104 3005 421 18962 1226 3337 742 1896 1516 
<----------------------------------------------------------------97 .4-------------------------------------------------------> 
Table 14 Gram-negative surveillance isolates: Percent susceptibility to 
ciprofloxacin of Dameron isolates compared to national survey 
~ :!! 
:l! .s l: 
~ 
.£: ~ i ~ ~ * ~ ~ ~ ~ ~ t 
I ~ I 8 ~ s ·5 i ~ 'o:f 'o:f 





Wl93.2 86.4 33.61 
2so 46798 27261 
+-
-..J Bold -~% sus<X.-ptihility 




1 JnuuiiiM ~n•n•mHIIIM-•••nll\.1 1 @, I. n-r , 
"'" O t .... ..... :t:! t • 
.!!! ~ I ~ ~ ~ ~ ~ 0 t ~ ~ I ::g 5i ~ :::J g. = j ~ ~ 111 rg !:1 ~ I u u !!! I ! 8 u 8 u 0 u 8 j 0 8 0 ~ ~ ! 'S.. ~ I -a. .c: i ~ ~ i l1 l? afi 
85.6 70.8 56.1 100 89.3 99.3 98.9 ---·---·-- ----- -----
2368 966 460 41 1924 143 543 
79.1 70.5 52.3 93.6 58.3 91.1 85.1 
.. ________ -- ,, ___ ., ____ --------- ----- ---
67586 18400 2560 1163 12682 426 4693 
Table 15 Gram-positive surveillance isolates: Percent susceptibility to 






NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS 
DOCU1viENT M2-A4 
Susceptible Intermediate Resistant 
Ciprofloxacin ( 5 ug) :515 16-18 :::19 
Norfloxacin ( 10. ug) :512 13-16 :::17 
Ofloxacin (5 ug) :512 13-15 :::16 
Lomefloxacin (1 0 ug) :518 19-21 :::22 
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